Publications
Sourisseau T, Maniotis D, McCarthy A, Tang C, Lord CJ, Ashworth A, Linardopoulos S. Aurora-A expressing tumour cells are deficient for homology-directed DNA double strand-break repair and sensitive to PARP inhibition. EMBO molecular medicine. 2010. PMID: 20373286
Geyer FC, Weigelt B, Natrajan R, Lambros MB, de Biase D, Vatcheva R, Savage K, Mackay A, Ashworth A, Reis-Filho JS. Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas. The Journal of pathology. 2010. PMID: 20099298
Olin RL, Kanetsky PA, Ten Have TR, Nasta SD, Schuster SJ, Andreadis C. Determinants of the optimal first-line therapy for follicular lymphoma: a decision analysis. American journal of hematology. 2010. PMID: 20196173
Harzstark AL, Small EJ. Castrate-resistant prostate cancer: therapeutic strategies. Expert opinion on pharmacotherapy. 2010. PMID: 20307219
Bradley DA, Daignault S, Ryan CJ, Dipaola RS, Cooney KA, Smith DC, Small E, Mathew P, Gross ME, Stein MN, Chen A, Pienta KJ, Escara-Wilke J, Doyle G, Al-Hawary M, Keller ET, Hussain M. Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium. Investigational new drugs. 2010. PMID: 20336348
Barnhart EL, Allen GM, Jülicher F, Theriot JA. Bipedal locomotion in crawling cells. Biophysical journal. 2010. PMID: 20303850
Martin SA, McCabe N, Mullarkey M, Cummins R, Burgess DJ, Nakabeppu Y, Oka S, Kay E, Lord CJ, Ashworth A. DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1. Cancer cell. 2010. PMID: 20227038
Kavanagh JJ, Levenback CF, Ramirez PT, Wolf JL, Moore CL, Jones MR, Meng L, Brown GL, Bast RC. Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer. Journal of hematology & oncology. 2010. PMID: 20222977
Chien AJ, Rugo HS. The cardiac safety of trastuzumab in the treatment of breast cancer. Expert opinion on drug safety. 2010. PMID: 20175700
Lilly MB, Ottmann OG, Shah NP, Larson RA, Reiffers JJ, Ehninger G, Müller MC, Charbonnier A, Bullorsky E, Dombret H, Brigid Bradley-Garelik M, Zhu C, Martinelli G. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study. American journal of hematology. 2010. PMID: 20131302
Escalón MP, Komanduri KV. Cord blood transplantation: evolving strategies to improve engraftment and immune reconstitution. Current opinion in oncology. 2010. PMID: 20180284
Wang SC, Parekh JR, Zuraek MB, Venook AP, Bergsland EK, Warren RS, Nakakura EK. Identification of unknown primary tumors in patients with neuroendocrine liver metastases. Archives of surgery (Chicago, Ill. : 1960). 2010. PMID: 20231629
Anderson MW, Zhao S, Ai WZ, Tibshirani R, Levy R, Lossos IS, Natkunam Y. C-C chemokine receptor 1 expression in human hematolymphoid neoplasia. American journal of clinical pathology. 2010. PMID: 20154287
Shunk R, Dulay M, Julian K, Cornett P, Kohlwes J, Tarter L, Hollander H, O'Brien B, O'Sullivan P. Using the american board of internal medicine practice improvement modules to teach internal medicine residents practice improvement. Journal of graduate medical education. 2010. PMID: 21975892
Campbell MR, Amin D, Moasser MM. HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010. PMID: 20179223
Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA, Natrajan R, Marchio C, Iorns E, Mackay A, Gillett C, Grigoriadis A, Tutt A, Reis-Filho JS, Ashworth A. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer research. 2010. PMID: 20179196
Hewish M, Lord CJ, Martin SA, Cunningham D, Ashworth A. Mismatch repair deficient colorectal cancer in the era of personalized treatment. Nature reviews. Clinical oncology. 2010. PMID: 20177404
Sun C, Su KH, Valentine J, Rosa-Bauza YT, Ellman JA, Elboudwarej O, Mukherjee B, Craik CS, Shuman MA, Chen FF, Zhang X. Time-resolved single-step protease activity quantification using nanoplasmonic resonator sensors. ACS nano. 2010. PMID: 20121209
Weigelt B, Mackay A, A'hern R, Natrajan R, Tan DS, Dowsett M, Ashworth A, Reis-Filho JS. Breast cancer molecular profiling with single sample predictors: a retrospective analysis. The Lancet. Oncology. 2010. PMID: 20181526
Wang YC, Zuraek MB, Kosaka Y, Ota Y, German MS, Deneris ES, Bergsland EK, Donner DB, Warren RS, Nakakura EK. The ETS oncogene family transcription factor FEV identifies serotonin-producing cells in normal and neoplastic small intestine. Endocrine-related cancer. 2010. PMID: 20048018